WS-07: Designs for vaccine and immunotherapy trials
نویسندگان
چکیده
منابع مشابه
HIV-1 Vaccine Trials: Evolving Concepts and Designs
An effective prophylactic HIV-1 vaccine is needed to eradicate the HIV/AIDS pandemic but designing such a vaccine is a challenge. Despite many advances in vaccine technology and approaches to generate both humoral and cellular immune responses, major phase-II and -III vaccine trials against HIV/AIDS have resulted in only moderate successes. The modest achievement of the phase-III RV144 prime-bo...
متن کاملAugmented designs to assess immune response in vaccine trials.
This article introduces methods for use in vaccine clinical trials to help determine whether the immune response to a vaccine is actually causing a reduction in the infection rate. This is not easy because immune response to the (say HIV) vaccine is only observed in the HIV vaccine arm. If we knew what the HIV-specific immune response in placebo recipients would have been, had they been vaccina...
متن کاملWS 06 / 07 of Florian Zickfeld
I have worked on the problems presented in this section with Stefan Felsner. A paper [8] is a available on the arXiv and a conference version [9] has been submitted. I will now outline what type of questions we consider and our main results. The concept of orientations with fixed out-degrees or α-orientations is a quite general one as we will see below. Let a graph G with vertex set V and a fun...
متن کاملDNA vaccine for cancer immunotherapy
DNA vaccination has emerged as an attractive immunotherapeutic approach against cancer due to its simplicity, stability, and safety. Results from numerous clinical trials have demonstrated that DNA vaccines are well tolerated by patients and do not trigger major adverse effects. DNA vaccines are also very cost effective and can be administered repeatedly for long-term protection. Despite all th...
متن کاملDesigner vaccine nanodiscs for personalized cancer immunotherapy
Despite the tremendous potential of peptide-based cancer vaccines, their efficacy has been limited in humans. Recent innovations in tumour exome sequencing have signalled the new era of personalized immunotherapy with patient-specific neoantigens, but a general methodology for stimulating strong CD8α+ cytotoxic T-lymphocyte (CTL) responses remains lacking. Here we demonstrate that high-density ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2007
ISSN: 1556-0864
DOI: 10.1097/01.jto.0000283072.85701.98